FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C	C. 20549
-----------------	----------

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL 3235-0287 OMB Number: Estimated average burden hours per response: 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b). Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person*     Moat Ross					2. Issuer Name and Ticker or Trading Symbol Kiniksa Pharmaceuticals, Ltd. [ KNSA ]							(Ch	eck all appli	•		ner			
(Last) (First) (Middle) C/O KINIKSA PHARMACEUTICALS, LTD. CLARENDON HOUSE 2 CHURCH STREET					3. Date of Earliest Transaction (Month/Day/Year) 09/02/2021								X Officer (give title Other (specify below) ARCALYST General Manager						
(Street) HAMILT			HM11 Zip)		4. If <i>i</i>	4. If Amendment, Date of Original Filed (Month/Day/Year)							Line	Individual or Joint/Group Filing (Check Applicable le)  X Form filed by One Reporting Person Form filed by More than One Reporting Person					
		Tab	le I - Non	-Deriva	ative	Sec	curitie	s Ac	quired, D	ispos	ed c	f, or Be	neficial	ly Owned	ı				
1. Title of Security (Instr. 3)  2. Transac Date (Month/Da					r)   E	A. Deem Execution f any Month/Da	Date	Transaction Dispose Code (Instr. 5)			ties Acquire d Of (D) (Ins		Benefici	es ally Following	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership (Instr. 4)		
								Code	/ Am	ount	(A) or (D) Price		Transaction(s) (Instr. 3 and 4)				msu. 4)		
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																			
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemee Execution I if any (Month/Day	Date, T	4. Transactior Code (Instr. 8)		n of		6. Date Exer Expiration D (Month/Day/	ate	e Amour ar) Securi Underl Deriva		. Title and kmount of securities Inderlying serivative Security Instr. 3 and 4)		9. Number derivative Securities Beneficiall Owned Following Reported Transactio (Instr. 4)	ly	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
				C	ode	v	(A)	(D)	Date Exercisable	Expirat Date	tion	Title	Amount or Number of Shares						
Share Option	\$12.97	09/02/2021			A		7,954		(1)	09/01/2	2031	Class A Common Shares	7,954	\$0	7,954		D		
Restricted Share Units	(2)	09/02/2021			A		3,977		(3)	(3)		Class A Common Shares	3,977	\$0	3,977		D		

- 1. The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in 36 equal monthly installments thereafter. The vesting commencement date is September 2, 2021.
- 2. Each Restricted Share Unit represents a contingent right to receive one Class A Common Share of the Issuer.
- 3. The Restricted Share Units (RSUs) vest over a four year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 2, 2021.

/s/ Madelyn Zeylikman, 09/07/2021 Attorney-in-Fact for Ross Moat

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.